thyroidpatientsca
-
Christmas 2020: Hope and cheer for thyroid patients
It’s been quite a year, so we send you good cheer. This season may be a socially-distanced experience for many of you, but still, you are not alone. We’re stronger together. We’re going to keep advancing thyroid science & policy, because our thyroid health outcomes matter. What are “thyroid” health outcomes? Heart & cardiovascular health…
-
Ingbar and Braverman’s historic study of LT4 monotherapy
As part of my post on “The thyroid gland is a T3 shield,” I reviewed a research article by Ingbar and team from 1982. Wow. What a treasure. The title of this article is “Elevated serum thyroxine concentration in patients receiving ‘replacement’ doses of levothyroxine.” Just look at that title. They began their title with…
-
Reverse T3 in the context of health status, dosages, and thyroid levels
A collection of research graphs and quotations showing diverse Reverse T3 levels coexisting with health, in various illnesses, and alongside various T3 and T4 levels.
-
Gullo: LT4 monotherapy and thyroid loss invert FT3 and FT4 per unit of TSH
In 2011, Gullo’s research team published a landmark study in thyroid therapy titled “Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients.” Gullo and colleagues examined the TSH, FT3 and FT4 levels and the FT3:FT4 ratios of 1,811 thyroidless patients on levothyroxine (LT4) monotherapy and compared them with 3,875 healthy controls. Gullo’s study shook the…
-
Normal FT3:FT4 thyroid hormone ratios in large populations
A normal ratio of Free T3 (FT3) to Free T4 (FT4) thyroid hormones appears to be a basic principle in thyroid hormone economy when no thyroid hormone dosing and no disease interfere. In this post, I provide graphs, quotations, and discussions from Gullo, Strich, and Anderson as I present their FT3:FT4 ratio results, and I…